GW Pharmaceuticals (GWPH) Upgraded to Hold at BidaskClub

GW Pharmaceuticals (NASDAQ:GWPH) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Other equities analysts have also recently issued reports about the stock. Leerink Swann boosted their target price on shares of GW Pharmaceuticals from $153.00 to $157.00 and gave the company an “outperform” rating in a research note on Tuesday, February 6th. Zacks Investment Research cut shares of GW Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Bank of America decreased their target price on shares of GW Pharmaceuticals from $154.00 to $149.00 and set a “buy” rating for the company in a research note on Tuesday, February 6th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $192.00 target price (down from $208.00) on shares of GW Pharmaceuticals in a research note on Monday, February 5th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $146.38.

Shares of NASDAQ GWPH opened at $123.95 on Friday. The company has a quick ratio of 11.34, a current ratio of 11.44 and a debt-to-equity ratio of 0.01. GW Pharmaceuticals has a 12 month low of $92.65 and a 12 month high of $143.37. The company has a market cap of $3,402.10, a price-to-earnings ratio of -17.83 and a beta of 2.62.



GW Pharmaceuticals (NASDAQ:GWPH) last posted its earnings results on Monday, February 5th. The biopharmaceutical company reported ($2.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.03) by ($0.40). GW Pharmaceuticals had a negative net margin of 1,357.98% and a negative return on equity of 46.94%. The firm had revenue of $7.73 million during the quarter, compared to analyst estimates of $2.18 million. equities research analysts forecast that GW Pharmaceuticals will post -9.66 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. Eqis Capital Management Inc. raised its position in GW Pharmaceuticals by 12.6% during the fourth quarter. Eqis Capital Management Inc. now owns 3,791 shares of the biopharmaceutical company’s stock worth $500,000 after acquiring an additional 424 shares during the period. Aperio Group LLC raised its position in GW Pharmaceuticals by 12.0% during the fourth quarter. Aperio Group LLC now owns 5,325 shares of the biopharmaceutical company’s stock worth $703,000 after acquiring an additional 569 shares during the period. Raymond James Financial Services Advisors Inc. raised its position in GW Pharmaceuticals by 18.1% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 4,371 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 671 shares during the period. Bank of Montreal Can raised its position in GW Pharmaceuticals by 37.1% during the fourth quarter. Bank of Montreal Can now owns 2,625 shares of the biopharmaceutical company’s stock worth $347,000 after acquiring an additional 710 shares during the period. Finally, Raymond James & Associates raised its position in GW Pharmaceuticals by 9.3% during the fourth quarter. Raymond James & Associates now owns 8,464 shares of the biopharmaceutical company’s stock worth $1,117,000 after acquiring an additional 718 shares during the period. Institutional investors own 82.51% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://dakotafinancialnews.com/2018/04/14/gw-pharmaceuticals-gwph-upgraded-to-hold-at-bidaskclub.html.

About GW Pharmaceuticals

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Analyst Recommendations for GW Pharmaceuticals (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply